Hepatitis C Virus

HCV-specific immune responses are associated with antiviral therapy nonresponse

Published in Hepatitis Weekly, April 24th, 2006

According to recently published research from the United States, hepatitis C virus (HCV)-specific immune responses and quasi-species (QS) variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

"Pretreatment HCV-specific lymphoproliferative (LP) responses, neutralizing antibody (NA) responses, intrahepatic cytotoxic T lymphocyte (CTL) responses, and HCV QS diversity and complexity were examined in patients with advanced hepatic fibrosis (Ishak fibrosis score of {{>=}}3) and prior nonresponse to interferon (IFN)-alpha therapy who were enrolled in the initial phase of the Hepatitis C Antiviral Long-Term Treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry